Inventiva (IVEVF) Total Non-Current Liabilities (2018 - 2025)
Inventiva (IVEVF) posted Total Non-Current Liabilities of $233.6 million for Q4 2025, up 59.45% on a QoQ basis from $146.5 million in Q2 2025, and up 108.4% year-over-year from $112.1 million in Q4 2024.
Analysis
Inventiva (IVEVF) Total Non-Current Liabilities (2018 - 2025) Analysis & Trends
Inventiva has reported Total Non-Current Liabilities for 8 years, with the latest figure at $233.6 million in Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities rose 108.4% year-over-year to $233.6 million in Q4 2025; TTM through Dec 2025 was $233.6 million, a 108.4% increase from a year earlier, with the FY2025 full-year figure at $233.6 million, up 108.4% from the prior year.
- Total Non-Current Liabilities was $233.6 million for Q4 2025 at Inventiva, up from $146.5 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $233.6 million in Q4 2025, with the low at $11.7 million in Q4 2021.
- Average Total Non-Current Liabilities over 5 years is $69.9 million, with a median of $44.3 million recorded in 2023.
- The largest YoY upside for Total Non-Current Liabilities was 745.32% in 2021 against a maximum downside of 28.62% in 2021.
- Over 5 years, Total Non-Current Liabilities stood at $11.7 million in 2021, then surged by 245.99% to $40.6 million in 2022, then soared by 36.19% to $55.3 million in 2023, then surged by 102.53% to $112.1 million in 2024, then soared by 108.4% to $233.6 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $233.6 million (Q4 2025), $146.5 million (Q2 2025), and $112.1 million (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn | 106.45 Bn |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn | 16.16 Bn |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | 100.86 Bn |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn | 32.04 Bn |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - | 1.53 Bn |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 1.40 Bn |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn | 607.80 Mn |
| 10 | Inventiva | 693.72 Mn | 693.72 Mn | - | 233.57 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 233.57 Mn |
| Jun 30, 2025 | 146.48 Mn |
| Dec 31, 2024 | 112.08 Mn |
| Jun 30, 2024 | 75.75 Mn |
| Dec 31, 2023 | 55.34 Mn |
| Jun 30, 2023 | 44.31 Mn |
| Dec 31, 2022 | 40.63 Mn |
| Jun 30, 2022 | 15.60 Mn |
| Dec 31, 2021 | 11.74 Mn |
| Jun 30, 2021 | 16.65 Mn |
| Mar 31, 2021 | 16.76 Mn |
| Dec 31, 2020 | 16.45 Mn |
| Jun 30, 2020 | 1.97 Mn |
| Dec 31, 2019 | 1.89 Mn |
| Dec 31, 2018 | 3.58 Mn |